Facet Life Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Facet Life Sciences operates as a specialized regulatory strategy and product development partner for emerging biotech companies, primarily in oncology and immunology. Founded in 2018 and based in San Francisco, the firm leverages deep FDA experience to design and execute tailored regulatory pathways, helping clients accelerate development and achieve key milestones like IND/IDE filings and NDA/BLA approvals. Its business model is purely service-based, offering integrated support across nonclinical, clinical, CMC, and commercial launch activities to bridge the gap between scientific innovation and market acceptance.

OncologyImmunology

Technology Platform

Integrated regulatory strategy and product development service platform, leveraging deep FDA experience, strategic statistical design, medical writing, and asset valuation expertise to guide client products.

Opportunities

The booming emerging biotech sector and increasing complexity of novel therapeutic modalities (e.g., cell/gene therapy, radiopharmaceuticals) create strong demand for specialized regulatory strategy services.

Facet's partnership model and focus on capital-efficient development position it as a critical enabler for small companies seeking to navigate the FDA successfully.

Risk Factors

Revenue is tied to the funding cycles of small biotech clients, making it vulnerable to sector downturns.

The service-based model faces competition from large CROs and boutiques, and its core asset—experienced personnel—is subject to talent retention risks.

Competitive Landscape

Facet competes in the regulatory affairs consulting segment against large, full-service CROs (like IQVIA, PPD) and smaller boutique consultancies. Its differentiation lies in a high-touch, strategic partnership model tailored specifically to the resource-constrained, agile needs of emerging biotech companies, contrasting with the more transactional or large-pharma-focused approaches of some competitors.

More companies in Digital Health & Biotech SaaS →More companies in United States →